OXT and pulmonary arterial hypertension: The World Health Organization (WHO) recommendation for pharmacological means of PPH prevention advocates the use of oxytocin (10 IU intramuscularly (IM) or intravenously (IV)) and carbetocin (if cost-effective), ergot alkaloids (alone or combined if there are no contraindications) or oral misoprostol in settings where oxytocin is not available or its quality cannot be guaranteed [4].